Main Article Content

Наталья Викторовна Коробкова
Светлана Алексеевна Зуева
Ольга Валерьевна Рохленко
Вадим Гельевич Мозес
Елена Владимировна Рудаева
Светлана Ивановна Елгина
Кира Борисовна Мозес
Яэль Центер
Наталья Степановна Черных

Abstract

Amyloidosis is a violation of protein metabolism, accompanied by the formation in tissues of a specific protein-polysaccharide complex (amyloid) of a fibrillar structure, characterized by a high orderliness of fibrils 5-10 nm thick due to the abundance of β-folded conformation in the secondary structure of the main amyloid-forming protein. The modern classification of amyloidosis is based on the principle of specificity of the main fibrillar amyloid precursor protein. Today, more than 36 amyloid precursor proteins have been identified in various human amyloidoses, among which at least 10 hereditary forms are distinguished. Among the listed hereditary forms, the most common is transthyretin amyloidosis (from the English. Amyloidosis transthyretin, ATTR): a fatal systemic progressive disease, manifested mainly by severe polyneuropathy, autonomic dysfunction and heart damage. Death occurs within 7-12 years from the onset of the disease in the absence of adequate treatment.

Keywords

TTR gene, hereditary amyloidosis, polyneuropathy, TTR-SAP, transtiretin

Author Biographies

Наталья Викторовна Коробкова,
neurologist
Светлана Алексеевна Зуева,
head of the neurological department
Ольга Валерьевна Рохленко,
neurologist
Вадим Гельевич Мозес,
doctor of medical sciences, docent, director of the Medical Institute; deputy chief physician for research activities
Елена Владимировна Рудаева,
candidate of medical sciences, docent, docent of the department of obstetrics and gynecology named after G.A. Ushakova
Светлана Ивановна Елгина,
doctor of medical sciences, docent, professor of department of obstetrics and gynecology N 1
Кира Борисовна Мозес,
assistant, department of polyclinic therapy and nursing
Яэль Центер,
pathologist
Наталья Степановна Черных,
candidate of medical sciences, docent, docent of the department of polyclinic pediatrics, propaedeutics of childhood diseases and postgraduate training

Article Details

Information about financing and conflict of interests

The study had no sponsorship.
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.

How to Cite

Коробкова, Н. В., Зуева, С. А., Рохленко, О. В., Мозес, В. Г., Рудаева, Е. В., Елгина, С. И., Мозес, К. Б., Центер, Я., & Черных, Н. С. (2023). TRANSTHYRETIN POLYNEUROPATHY (CLINICAL CASE). Medicine in Kuzbass, 22(3), 75-78. https://doi.org/10.24412/2687-0053-2023-3-75-78

References

Klimtchuk ES, Prokaeva T, Frame NM, Abdullahi HA, Spencer B, Dasari S, et al. Unusual duplica- tion mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease. Proc Natl Acad Sci USA. 2018; 115: E6428-E6436. doi: 10.1073/pnas.1802977115

Koike H, Katsuno M. Ultrastructure in transthyretin amyloid- osis: from pathophysiology to therapeutic insights. Biomedicines. 2019; 7(1): 11. doi: 10.3390/biomedicines7010011

Mangione PP, Verona G, Corazza A, Marcoux J, Canetti D, Giorgetti S, et al. Plasminogen activa- tion triggers transthyretin amyloidogenesis in vitro. J Biol Chem. 2018; 293(37): 14192-14199. doi: 10.1074/jbc.RA118.003990

Adams D, Suhr OB, Hund E, Obici L, Tournev I, Campistol JM, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016; 29(Suppl. 1): S14-26. doi: 10.1097/WCO.0000000000000289

Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017; 23(7 Suppl): S107-S112

Naumova ES, Nikitin SS, Adyan TA, Druzhinin DS, Varshavskiy VA. Misdiagnosed case of transthyretin amyloidosis in a fully investigated patient. Neuromuscular Diseases. 2018; 8(1): 46-52. Russian (Наумова Е.С., Никитин С.С., Адян Т.А., Дружинин Д.С., Варшавский В.А. Клинический случай транстиретинового амилоидоза с задержкой верификации диагноза у полностью обследованной больной //Нервно-мышечные болезни. 2018. Т. 8, № 1. С. 42-56.) doi: 10.17650/2222-8721-2018-8-1-46-52

Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang Ch-Ch, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018; 379(1): 11-21. doi: 10.1056/NEJMoa1716153

Rameev VV. Recent methods of diagnosis and treatment of hereditary transthyretin amyloidosis. Manage pain. 2018; 1: 20-24. Russian (Рамеев В.В. Современные методы диагностики и лечения транстиретинового наследственного амилоидоза //Manage pain. 2018. № 1. С. 20-24)

Ruger J, Ioannou S, Castanotto D, Stein CA. Oligonucleotides to the (Gene) Rescue: FDA Approvals 2017-2019. Trends Pharmacol Sci. 2020; 41(1): 27-41. doi: 10.1016/j.tips.2019.10.009

Gales L. Tegsedi (Inotersen): An antisense oligonucleotide approved for the treatment of adult patients with hereditary transthyretin amyloidosis. Pharmaceuticals (Basel). 2019; 12(2): 78. doi: 10.3390/ph1202007810.3390/ph12020078

Downloads

Download data is not yet available.

Most read articles by the same author(s)

<< < 4 5 6 7 8 9 10 11 12 > >>